These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16960471)

  • 41. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levetiracetam as a treatment for tardive dyskinesia: a case report.
    McGavin CL; John V; Musser WS
    Neurology; 2003 Aug; 61(3):419. PubMed ID: 12913217
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study.
    López-Góngora M; Martínez-Domeño A; García C; Escartín A
    Epileptic Disord; 2008 Dec; 10(4):297-305. PubMed ID: 19017572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levetiracetam in absence epilepsy.
    Verrotti A; Cerminara C; Domizio S; Mohn A; Franzoni E; Coppola G; Zamponi N; Parisi P; Iannetti P; Curatolo P
    Dev Med Child Neurol; 2008 Nov; 50(11):850-3. PubMed ID: 18808424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of tardive dyskinesia in affective disorder patients.
    Yassa R; Ghadirian AM; Schwartz G
    J Clin Psychiatry; 1983 Nov; 44(11):410-2. PubMed ID: 6139365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tardive dyskinesia: determinants of temporal dynamics of its emergence.
    Latalova K
    Neuro Endocrinol Lett; 2008 Dec; 29(6):995-8. PubMed ID: 19112392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study.
    Raja M; Azzoni A
    Hum Psychopharmacol; 2002 Jan; 17(1):61-3. PubMed ID: 12404708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study.
    Hamza MS; Anderson DG; Snyder JW; Deschner S; Cifu DX
    PM R; 2009 Apr; 1(4):335-9. PubMed ID: 19627916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model.
    Singh MM; Becker RE; Pitman RK; Nasrallah HA; Lal H; Dufresne RL; Weber SS; McCalley-Whitters M
    Biol Psychiatry; 1982 Jun; 17(6):729-42. PubMed ID: 6125219
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 51. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients.
    Szucs A; Clemens Z; Jakus R; Rásonyi G; Fabó D; Holló A; Barcs G; Kelemen A; Janszky J
    Epilepsia; 2008 Jul; 49(7):1174-9. PubMed ID: 18479387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid dosage titration of levetiracetam in children.
    Vaisleib II; Neft RA
    Pharmacotherapy; 2008 Mar; 28(3):393-6. PubMed ID: 18294118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of levetiracetam in hemifacial spasm: a case report.
    Biagio Carrieri P; Petracca M; Montella S
    Clin Neuropharmacol; 2008; 31(3):187-8. PubMed ID: 18520988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disfluent speech in patients with partial epilepsy: beneficial effect of levetiracetam.
    Sechi G; Cocco GA; D'Onofrio M; Deriu MG; Rosati G
    Epilepsy Behav; 2006 Nov; 9(3):521-3. PubMed ID: 16971185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tardive dyskinesia and glucid metabolism.
    Brousse G; Meary A; Mouret J; Blanc O; Hueber T; Lemoine P; Llorca PM; Lachaux B
    Hum Psychopharmacol; 2007 Aug; 22(6):373-80. PubMed ID: 17579925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
    Karniol IG; Giampietro AC; Moura DS; Vilela WA; Oliveira MA; Zuardi AW
    Acta Psiquiatr Psicol Am Lat; 1983 Dec; 29(4):261-6. PubMed ID: 6369888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of tardive dyskinesia with risperidone: a case report.
    Kooptiwoot S; Settachan T
    J Med Assoc Thai; 2000 Nov; 83(11):1430-2. PubMed ID: 11215878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Persistent movement disorders induced by buspirone.
    LeWitt PA; Walters A; Hening W; McHale D
    Mov Disord; 1993 Jul; 8(3):331-4. PubMed ID: 8101969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Historical perspective on movement disorders.
    Friedman JH
    J Clin Psychiatry; 2004; 65 Suppl 9():3-8. PubMed ID: 15189105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.